Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin - solution for injection - 1 mg/ml - active: buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin excipient: benzyl alcohol monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide water for injection - for the treatment of endometriosis not primarily requiring surgical treatment. pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - atovaquone 250mg; proguanil hydrochloride 100mg - film coated tablet - active: atovaquone 250mg proguanil hydrochloride 100mg excipient: colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry brown 03c86943 poloxamer sodium starch glycolate tolpovidone i 131 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for: · prophylaxis of plasmodium falciparum malaria in adults · treatment of plasmodium falciparum malaria in adults.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 800mg; sevelamer carbonate 800mg - film coated tablet - 800 mg - active: sevelamer carbonate 800mg excipient: isopropyl alcohol microcrystalline cellulose opacode opadry clear propylene glycol sodium chloride zinc stearate active: sevelamer carbonate 800mg excipient: acetylated monoglycerides hypromellose e-15 hypromellose e-5 isopropyl alcohol microcrystalline cellulose opacode propylene glycol sodium chloride zinc stearate - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 1600mg - powder for oral suspension - 1.6 g - active: sevelamer carbonate 1600mg excipient: 'natural and artificial citrus cream' proprietary flavouring iron oxide yellow propylene glycol alginate sodium chloride sucralose - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 2400mg - powder for oral suspension - 2.4 g - active: sevelamer carbonate 2400mg excipient: 'natural and artificial citrus cream' proprietary flavouring iron oxide yellow propylene glycol alginate sodium chloride sucralose - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100 mg/ml;   - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml   excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100mg;  ;  ; amisulpride 100mg - tablet - 100 mg - active: amisulpride 100mg     excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 100mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 200mg;  ;  ; amisulpride 200mg - tablet - 200 mg - active: amisulpride 200mg     excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 200mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.